Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

NCT06709495 is registered in ClinicalTrials.gov with David S Shulman, MD as lead sponsor.

NCT NCT06709495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06709495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Lead sponsor
David S Shulman, MD
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 27, 2025
Completion date
September 1, 2029
Enrollment
63 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

desmoplastic small round cell tumor, osteosarcoma, refractory sarcoma, rhabdomyosarcoma, sarcoma, sarcoma, ewing